- Home
- PBYI vs PIM Comparison
PBYI vs PIM Comparison
Compare PBYI & PIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- PIM
- Stock Information
- Founded
- PBYI 2010
- PIM 1988
- Country
- PBYI United States
- PIM United States
- Employees
- PBYI N/A
- PIM N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- PIM Finance Companies
- Sector
- PBYI Health Care
- PIM Finance
- Exchange
- PBYI Nasdaq
- PIM Nasdaq
- Market Cap
- PBYI 176.1M
- PIM 162.4M
- IPO Year
- PBYI N/A
- PIM N/A
- Fundamental
- Price
- PBYI $2.60
- PIM $3.41
- Analyst Decision
- PBYI Strong Buy
- PIM
- Analyst Count
- PBYI 1
- PIM 0
- Target Price
- PBYI $7.00
- PIM N/A
- AVG Volume (30 Days)
- PBYI 310.0K
- PIM 57.5K
- Earning Date
- PBYI 10-31-2024
- PIM 01-01-0001
- Dividend Yield
- PBYI N/A
- PIM 8.28%
- EPS Growth
- PBYI N/A
- PIM N/A
- EPS
- PBYI 0.18
- PIM 0.05
- Revenue
- PBYI $219,143,000.00
- PIM N/A
- Revenue This Year
- PBYI N/A
- PIM N/A
- Revenue Next Year
- PBYI N/A
- PIM N/A
- P/E Ratio
- PBYI $14.06
- PIM $63.80
- Revenue Growth
- PBYI N/A
- PIM N/A
- 52 Week Low
- PBYI $2.13
- PIM $2.90
- 52 Week High
- PBYI $7.73
- PIM $3.28
- Technical
- Relative Strength Index (RSI)
- PBYI 47.40
- PIM 62.51
- Support Level
- PBYI $2.48
- PIM $3.34
- Resistance Level
- PBYI $2.64
- PIM $3.45
- Average True Range (ATR)
- PBYI 0.14
- PIM 0.04
- MACD
- PBYI 0.06
- PIM 0.00
- Stochastic Oscillator
- PBYI 85.06
- PIM 67.50
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.